Neurology Department, Instituto de Investigaciones Médicas Alfredo Lanari, Av. Combatientes de Malvinas 3150, Buenos Aires, Argentina.
III Normal Anatomy Department (Living Anatomy Laboratory), School of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Acta Neurol Belg. 2021 Dec;121(6):1519-1523. doi: 10.1007/s13760-020-01382-7. Epub 2020 May 20.
Since 2015, edaravone is the second drug available for the treatment of Amyotrophic lateral sclerosis (ALS). In this study we analyzed the characteristics and experience of ALS patients treated with this new medication in our country. Sixteen ALS patients were treated with edaravone infusions in three ALS clinics. Most of them were male, had a spinal onset of the disease and a definite diagnosis of ALS. Mean age at first infusion was 53.5 years. Since the diagnosis of ALS, delay in starting treatment with edaravone was five times greater than that of riluzole. Edaravone therapy was usually initiated at a health care facility and was followed by domiciliary cycles. Adverse effects and the need of a special catheter for infusion were rare. Access to edaravone through health insurance was possible in only 43.8% of patients. Altogether, treatment access was limited but feasible and edaravone was well tolerated.
自 2015 年以来，依达拉奉是第二种可用于治疗肌萎缩侧索硬化症（ALS）的药物。在本研究中，我们分析了在我国使用这种新药物治疗的 ALS 患者的特征和经验。在三家 ALS 诊所中，有 16 名 ALS 患者接受了依达拉奉输注治疗。他们大多数是男性，疾病从脊髓开始，且有明确的 ALS 诊断。首次输注时的平均年龄为 53.5 岁。从 ALS 诊断开始，与利鲁唑相比，开始使用依达拉奉治疗的延迟时间要多出五倍。依达拉奉治疗通常在医疗机构开始，并随后进行家庭治疗周期。不良反应和输注专用导管的需求很少见。只有 43.8%的患者可以通过健康保险获得依达拉奉。总的来说，治疗途径是有限的，但却是可行的，并且依达拉奉耐受性良好。
